Vaccination responses to capsular polysaccharides of Neisseria meningitidis and Haemophilus influenzae type b in two C2-deficient sisters: alternative pathway-mediated bacterial killing and evidence for a novel type of blocking IgG.
Meningitis caused by Neisseria meningitidis serogroup W-135 was diagnosed in a 14-year-old girl with a history of neonatal septicemia and meningitis caused by group B streptococci type III. C2 deficiency type I was found in the patient and her healthy sister. Both sisters were vaccinated with tetravalent meningococcal vaccine and a conjugate Haemophilus influenzae type b vaccine. Three main points emerged from the analysis. First, vaccination resulted in serum bactericidal responses demonstrating anticapsular antibody-mediated recruitment of the alternative pathway. Second, addition of C2 to prevaccination sera produced bactericidal activity in the absence of anticapsular antibodies, which suggested that the bactericidal action of antibodies to subcapsular antigens detected in the sera might strictly depend on the classical pathway. A third point concerned a previously unrecognized type of blocking activity. Thus, postvaccination sera of the healthy sister contained IgG that inhibited killing of serogroup W-135 in C2-deficient serum, and the deposition of C3 on enzyme-linked immunosorbent assay plates coated with purified W-135 polysaccharide. Our findings suggested blocking to be serogroup-specific and dependent on early classical pathway components. Retained opsonic activity probably supported post-vaccination immunity despite blocking of the bactericidal activity. The demonstration of functional vaccination responses with recruitment of alternative pathway-mediated defense should encourage further trial of capsular vaccines in classical pathway deficiency states.
Selander
B
B
Institute of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund University, Sweden.
Käyhty
H
H
Wedege
E
E
Holmström
E
E
Truedsson
L
L
Söderström
C
C
Sjöholm
A G
AG
D000293:Adolescent; D019138:Antibodies, Blocking / Q000096:biosynthesis; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology*; D002352:Carrier Proteins; D002675:Child, Preschool; D003175:Complement C2 / Q000172:deficiency* / Q000276:immunology; D003170:Complement Pathway, Alternative / Q000276:immunology*; D005260:Female; D005819:Genetic Markers / Q000276:immunology; D018073:Haemophilus Vaccines / Q000276:immunology*; D019741:Haemophilus influenzae type b / Q000276:immunology*; D006801:Humans; D018960:Hyaluronan Receptors; D007074:Immunoglobulin G / Q000096:biosynthesis*; D008562:Membrane Glycoproteins; D008583:Meningitis, Haemophilus / Q000276:immunology*; D008585:Meningitis, Meningococcal / Q000276:immunology*; D024101:Mitochondrial Proteins; D009345:Neisseria meningitidis / Q000276:immunology*; D009895:Opsonin Proteins / Q000378:metabolism; D010587:Phagocytosis / Q000276:immunology; D011135:Polysaccharides, Bacterial / Q000276:immunology*; D011951:Receptors, Complement / Q000378:metabolism; D012703:Serotyping; D015164:Vaccines, Inactivated / Q000276:immunology
D019138:Antibodies, Blocking; D001425:Bacterial Outer Membrane Proteins; C087299:C1QBP protein, human; D002352:Carrier Proteins; D003175:Complement C2; D005819:Genetic Markers; D018073:Haemophilus Vaccines; C061964:Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine; D018960:Hyaluronan Receptors; D007074:Immunoglobulin G; D008562:Membrane Glycoproteins; D024101:Mitochondrial Proteins; D009895:Opsonin Proteins; D011135:Polysaccharides, Bacterial; D011951:Receptors, Complement; D015164:Vaccines, Inactivated; C032402:complement 1q receptor